Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease non-alcoholic fatty liver disease
Symptom C0239946|liver fibrosis
Sentences 20
PubMedID- 23626613 furthermore, the risk of thrombosis in patients with non-alcoholic fatty liver disease was associated with advanced liver fibrosis and nonalcoholic steatohepatitis.
PubMedID- 26494963 liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
PubMedID- 23710314 Background/aims: the bard score is a model to detect advanced liver fibrosis in nonalcoholic fatty liver disease (nafld) patients.
PubMedID- 23258240 Predictors of liver fibrosis in patients with non-alcoholic fatty liver disease.
PubMedID- 25326152 Background: accurately evaluating liver fibrosis in patients with non-alcoholic fatty liver disease (nafld) is important for identifying those who may develop complications.
PubMedID- 19931264 Hfe genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.
PubMedID- 24628717 Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: proceed with caution.
PubMedID- 22168074 Elastography efficiency in the liver fibrosis determination in patients with nonalcoholic fatty liver disease.
PubMedID- 22140659 Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.
PubMedID- 22045426 Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.
PubMedID- 20373368 Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
PubMedID- 24798049 The combination of liver stiffness measurement and nafld fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
PubMedID- 20526777 Objective: transient elastography (te) has shown promising results for the staging of liver fibrosis in patients with non-alcoholic fatty liver disease (nafld) and steatohepatitis (nash) with the limitation that 25% of obese patients cannot be examined with the standard te probe.
PubMedID- 25836944 Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
PubMedID- 25608776 The aim of our pilot study was to assess the clinical performance of the apparent diffusion coefficient (adc) of liver parenchyma for the assessment of liver fibrosis in patients with non-alcoholic fatty liver disease (nafld).
PubMedID- 22087183 The major finding of their study was that the apri also had an acceptable accuracy for the assessment of liver fibrosis in patients with nonalcoholic fatty liver disease (nafld), tending to increase with the degree of fibrosis.
PubMedID- 24342745 Background & aims: series studies have associated increased serum levels of ferritin with liver fibrosis in patients with nonalcoholic fatty liver disease.
PubMedID- 20540856 Conclusions: both timp-1 and -2 may reflect the state of liver fibrosis in children with nonalcoholic fatty liver disease, and serum timp-1 appears to be more reliable.
PubMedID- 23480804 liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice.
PubMedID- 26049707 Objective: the purpose of this study was to noninvasively estimate disease activity and liver fibrosis in patients with nonalcoholic fatty liver disease (nafld) using anthropometric and biochemical characteristics and the c-methionine breath test (mebt).

Page: 1